Targeted Combination Therapy Approved for BRAF-mutated Metastatic Colorectal Cancer
The FDA has converted the accelerated approval of encorafenib and cetuximab plus chemotherapy to full approval for first-line treatment...
Progress Against Cancer
The FDA has converted the accelerated approval of encorafenib and cetuximab plus chemotherapy to full approval for first-line treatment...
The second-generation BTK inhibitor acalabrutinib was approved for use with venetoclax. The U.S. Food and Drug Administration (FDA) approved...
The FDA has approved the portable device Optune Pax for non-invasive at-home treatment of locally advanced pancreatic cancer. The...
Pembrolizumab plus paclitaxel, with or without bevacizumab, was approved for PD-L1-positive ovarian, fallopian tube, and peritoneal cancers. The U.S....
The FDA has approved daratumumab and hyaluronidase-fihj in combination with other therapies as first-line treatment for certain patients with...
Patients now have the option of receiving the bispecific antibody amivantamab as an injection. The U.S. Food and Drug...
The FDA has converted the accelerated approval of rucaparib to full approval for certain patients with metastatic castration-resistant prostate...
Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration...
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent plus a corticosteroid for...
Lisocabtagene maraleucel was granted approval for adults with treatment-resistant marginal zone lymphoma. The U.S. Food and Drug Administration (FDA)...